A Clinical Trial Evaluating the Influence of the Ingredients MyCondro™ and Bovine Chondroitin Sulfate on the Behavior of Cells in the Osteoarticular Sphere

The study evaluates the effect of chondroitin sulfate derived from fermentation (MyCondro™) and bovine chondroitin sulfate, on the health and function of the skeletal system ex vivo, including cartilage, joint capsule, and bone tissue. The primary aim of the study is to determine the influence of human sera enriched with metabolites resulting from the ingestion of the ingredients on the metabolism of human primary cells of cartilage (chondrocytes), joint capsule (synoviocytes) and bone tissue (osteoblasts). Furthermore, the absorption kinetics of MyCondro™ and Bovine CS will be described.

Inclusion Criteria: * Men. * 18-35 years old (terminals included). * Liver test in the reference standards. * Renal assessment in the reference standards. * NFS in the reference standards. * CRP in the reference standards. * Blood pressure compatible with the conduct of the study. * Non-smoker or occasional smoker (\3 glasses of alcohol per day for men). * Ongoing treatment (medication, dietary supplement or probiotic) and within 4 weeks prior to inclusion. * Known pathology (including seasonal). * Allergy to the study product (all types) * People with a diet that is not suitable for the conduct of the study (e.g. vegetarian, vegan or vegan diet). * Change in eating habits in the 4 weeks prior to inclusion. * Medical and/or surgical history judged by the investigator or his/her representative to be incompatible with the trial. * Blood donation made in the 3 months prior to the inclusion visit or intending to do so during the study. * Persons under guardianship, curatorship, deprivation of liberty, safeguard of justice. * Refusal to sign the information sheet and consent. * Refusal to be registered on the National Register of Volunteers who lend themselves to research involving the human person. * Person who is excluded from another study on the national volunteer database, or who has received more than €6000 in the year following their participation in clinical studies.